You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

CLINICAL TRIALS PROFILE FOR DEPAKOTE ER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Depakote Er

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005015 ↗ Treatment of Depression in Youth With Bipolar Disorders Terminated National Institute of Mental Health (NIMH) Phase 3 1969-12-31 THIS STUDY HAS BEEN DISCONTINUED. The study is designed to evaluate the safety and efficacy of fluoxetine for treating children and adolescents with Bipolar Disorder who are experiencing an episode of major depression while being treated with a mood stabilizer. The study involves a 2-week assessment period. Patients who are on stable, therapeutic doses of lithium or valproate and continue to have depression will be randomized to a 12-week treatment of fluoxetine or placebo. Those who respond favorably to treatment will be followed openly for an 18-week continuation phase.
NCT00048802 ↗ Treatment and Outcome of Early Onset Bipolar Disorder Completed National Institute of Mental Health (NIMH) Phase 4 2002-08-01 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00048802 ↗ Treatment and Outcome of Early Onset Bipolar Disorder Completed Northwell Health Phase 4 2002-08-01 This study will compare the effectiveness in the maintenance of continuing adjunctive atypical antipsychotic medication compared to traditional mood stabilizer(s) alone in the maintenance treatment of adolescents with bipolar disorder.
NCT00057681 ↗ Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed National Institute of Mental Health (NIMH) Phase 3 2003-02-01 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00057681 ↗ Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed Washington University School of Medicine Phase 3 2003-02-01 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Depakote Er

Condition Name

Condition Name for Depakote Er
Intervention Trials
Bipolar Disorder 26
Healthy 16
Schizophrenia 4
Mania 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Depakote Er
Intervention Trials
Bipolar Disorder 32
Disease 24
Depression 5
Mood Disorders 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Depakote Er

Trials by Country

Trials by Country for Depakote Er
Location Trials
United States 205
India 8
Canada 3
Korea, Republic of 2
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Depakote Er
Location Trials
Texas 17
Ohio 15
Illinois 13
California 13
New York 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Depakote Er

Clinical Trial Phase

Clinical Trial Phase for Depakote Er
Clinical Trial Phase Trials
Phase 4 29
Phase 3 18
Phase 2/Phase 3 1
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Depakote Er
Clinical Trial Phase Trials
Completed 73
Terminated 10
Unknown status 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Depakote Er

Sponsor Name

Sponsor Name for Depakote Er
Sponsor Trials
Abbott 33
National Institute of Mental Health (NIMH) 10
Dr. Reddy's Laboratories Limited 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Depakote Er
Sponsor Trials
Other 79
Industry 63
NIH 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Divalproex Sodium (Depakote ER): Clinical Trials, Market Analysis, and Projections

Last updated: January 4, 2025

Introduction to Divalproex Sodium (Depakote ER)

Divalproex sodium, marketed under the brand name Depakote ER, is a medication widely used for the treatment of various neurological and psychiatric conditions. It is an extended-release formulation of valproate, designed for once-daily oral administration. Here, we will delve into the clinical trials, market analysis, and projections for this drug.

Clinical Trials and Efficacy

Mania in Bipolar Disorder

Clinical trials have demonstrated the efficacy of divalproex ER in treating acute manic or mixed episodes associated with bipolar I disorder. A randomized, placebo-controlled study involving 377 patients hospitalized for acute mania showed that divalproex ER significantly improved symptoms compared to placebo. Patients receiving divalproex ER had greater improvements on the Mania Rating Scale (MRS) at all assessment points from day 5 through day 21. Additionally, 48% of patients on divalproex ER achieved at least a 50% improvement in MRS scores, compared to 34% on placebo[1].

Epilepsy

Depakote ER is also indicated for the treatment of complex partial seizures, simple and complex absence seizures, and as adjunctive therapy in patients with multiple seizure types. Clinical studies have supported its effectiveness in these indications, with dosages typically initiated at 10 to 15 mg/kg/day and adjusted to achieve optimal clinical response within the therapeutic range of 50 to 100 mcg/mL[3][4].

Migraine Prophylaxis

For the prophylaxis of migraine headaches, Depakote ER has been shown to be effective, with a recommended starting dose of 500 mg once daily, increasing to 1,000 mg once daily after one week. The effective dose range for migraine prophylaxis is generally between 500 to 1,000 mg/day[3][4].

Safety and Side Effects

While Depakote ER is effective, it comes with several safety considerations. Common side effects include somnolence, dizziness, and gastrointestinal complaints. More serious risks include hepatotoxicity, particularly in patients with mitochondrial disorders, and an increased risk of birth defects and suicidal tendencies. Therefore, its use must be carefully monitored, especially in vulnerable patient groups[1][3][4].

Market Analysis

Market Size and Growth

The global divalproex sodium market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.2% from 2022 to 2027. This growth is driven by increasing incidence rates of bipolar disorders, epilepsy, and migraine headaches, as well as expanding government initiatives and research and development activities[2].

Regional Market Share

North America, particularly the United States, holds the largest market share due to high prevalence rates of epilepsy and migraine. The Asia-Pacific region is expected to be the fastest-growing market during the forecast period, driven by a large patient pool and increasing healthcare expenditures[2].

Key Players

Major players in the divalproex sodium market include AbbVie Inc., Lupin Pharmaceuticals, Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, and Aurobindo Pharma. These companies are involved in various strategies such as new product launches, technological advancements, and strategic partnerships to maintain their market positions[2].

Market Drivers

Growing Incidence Rates of Bipolar Disorders and Epilepsy

The increasing prevalence of bipolar disorders and epilepsy globally is a significant driver for the divalproex sodium market. According to the World Health Organization, approximately 50 million people worldwide suffer from epilepsy, making it one of the most common neurological diseases[2].

Expanding Patient Pool with Migraine Headaches

Migraine headaches also contribute to the demand for divalproex sodium. In the United States, for example, 17.1% of women and 5.6% of men report having migraine symptoms, which further boosts the market growth[2].

Increasing Government Initiatives and R&D Activities

Government initiatives and rising research and development activities aimed at launching new products and improving existing ones are also driving the market. These efforts enhance the availability and accessibility of divalproex sodium, contributing to its growing demand[2].

Market Restraints

Stringent Regulations

The divalproex sodium market faces challenges from stringent regulatory requirements. Regulatory bodies closely monitor the safety and efficacy of drugs, which can sometimes delay market approvals and affect sales[2].

Neurobehavioral Adverse Effects

The use of divalproex sodium is associated with neurobehavioral adverse effects, birth defects, and suicidal tendencies, which can limit its adoption. These risks necessitate careful patient selection and monitoring, potentially constraining market growth[2].

Porter's Five Forces Analysis

Threat of New Entrants

The threat of new entrants in the divalproex sodium market is low due to the high barriers to entry, including stringent regulatory requirements and the need for significant investment in research and development[2].

Bargaining Power of Buyers/Consumers

The bargaining power of buyers is moderate, as patients and healthcare providers have some flexibility in choosing between different brands and formulations of divalproex sodium. However, the presence of major players and the complexity of the drug limit this power[2].

Bargaining Power of Suppliers

The bargaining power of suppliers is relatively low, as the market is characterized by a low concentration of suppliers. This makes it easier for manufacturers to negotiate prices and terms[2].

Threat of Substitute Products

The threat of substitute products is moderate, as there are other antiepileptic and mood-stabilizing drugs available. However, divalproex sodium's broad range of indications and established efficacy make it a preferred choice for many patients[2].

Intensity of Competitive Rivalry

The intensity of competitive rivalry in the divalproex sodium market is high, with several major players competing for market share. This competition drives innovation and pricing strategies, but also increases the complexity of the market landscape[2].

Future Projections

Market Growth

The divalproex sodium market is expected to continue growing, driven by the increasing prevalence of neurological and psychiatric disorders, along with advancements in healthcare infrastructure and government initiatives. The Asia-Pacific region is anticipated to be a key growth area due to its large and growing patient population[2].

New Product Launches and R&D

Ongoing research and development activities are likely to introduce new formulations and delivery systems for divalproex sodium, enhancing its efficacy and safety profile. These innovations will further drive market growth and expand the drug's therapeutic applications[5].

Key Takeaways

  • Clinical Efficacy: Divalproex ER is effective in treating mania in bipolar disorder, epilepsy, and migraine prophylaxis.
  • Market Growth: The global divalproex sodium market is projected to grow at a CAGR of 6.2% from 2022 to 2027.
  • Regional Dynamics: North America holds the largest market share, while the Asia-Pacific region is expected to be the fastest-growing market.
  • Market Drivers: Growing incidence rates of bipolar disorders, epilepsy, and migraine headaches, along with increasing government initiatives and R&D activities.
  • Market Restraints: Stringent regulations, neurobehavioral adverse effects, and the risk of birth defects and suicidal tendencies.

FAQs

What are the primary indications for Depakote ER?

Depakote ER is indicated for the acute treatment of manic or mixed episodes associated with bipolar disorder, monotherapy and adjunctive therapy of complex partial seizures and absence seizures, and prophylaxis of migraine headaches[3][4].

What is the recommended dosage for Depakote ER in treating mania?

The initial dose for mania is 25 mg/kg/day, increasing as rapidly as possible to achieve therapeutic response or desired plasma levels[3][4].

Which region is expected to be the fastest-growing market for divalproex sodium?

The Asia-Pacific region is expected to be the fastest-growing market for divalproex sodium during the forecast period[2].

What are the common side effects associated with Depakote ER?

Common side effects include somnolence, dizziness, and gastrointestinal complaints. More serious risks include hepatotoxicity, birth defects, and suicidal tendencies[1][3][4].

Who are the major players in the global divalproex sodium market?

Major players include AbbVie Inc., Lupin Pharmaceuticals, Inc., Dr. Reddy's Laboratories Ltd., Zydus Cadila, and Aurobindo Pharma[2].

Sources

  1. Clinical Trials: "A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania associated with bipolar I disorder" - PubMed[1].
  2. Market Analysis: "Divalproex Sodium Market Size & Share Analysis" - Mordor Intelligence[2].
  3. FDA Label: "Depakote ER (divalproex sodium) extended-release tablets" - FDA[3].
  4. FDA Label Update: "Depakote ER (divalproex sodium) extended-release tablets" - FDA[4].
  5. Market Report: "Divalproex Sodium Market Statistical Forecast, Trade Analysis" - OpenPR[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.